The American Association of Pharmaceutical Scientists (AAPS) has unveiled a transformative agenda for its 2026 PharmSci 360 conference, slated for October 25–28, 2026, at the Ernest N. Morial Convention Center in New Orleans. Recognizing the dual pressures of an AI-driven information explosion and a regulatory shift away from traditional animal models, the organization is introducing two "Innovator-Curated" tracks designed to address the foundational pillars of modern pharmaceutical development: scientific integrity and the evolution of testing methodologies.
As the pharmaceutical industry faces increasing scrutiny over the reproducibility of preclinical data and the ethical, economic, and scientific limitations of animal testing, these specialized tracks represent a strategic effort by AAPS to provide a roadmap for researchers, policymakers, and industry leaders.
The Integrity Crisis: Navigating Research in the AI Era
The first curated track, scheduled for Monday, October 26, tackles the precarious state of scientific literature. With the rapid proliferation of generative artificial intelligence, the scientific community is grappling with a rise in low-quality or fraudulent manuscripts that threaten to undermine evidence-based medicine. Brian Nosek, co-founder and executive director of the Center for Open Science, will anchor this program. His keynote, "Trustworthiness in the Age of Acceleration," will set the stage for a critical evaluation of how the industry can preserve the sanctity of the scientific record.
The track will move beyond theoretical concerns to address the mechanical failures in current research pipelines. A morning symposium will dissect the systemic factors that enable scientific fraud, focusing on the role of predatory publishing and the limitations of peer review in an era of high-volume submissions. The symposium will also synthesize lessons from large-scale replication projects in oncology, where historically low reproducibility rates have delayed the development of life-saving therapeutics.
Participants will engage with researchers and policymakers to identify technical solutions, including automated tools for citation verification and the establishment of "ethical AI" guidelines for drug discovery. Maryam Zaringhalam of the Center for Open Science will facilitate these discussions, aiming to align academic rigor with the fast-paced demands of corporate pharmaceutical development.
The Transition to New Approach Methodologies (NAMs)
Two days later, on October 28, the conference will pivot to the technical and regulatory frontier of drug development: the replacement of animal models. Led by Professor Thomas Hartung of Johns Hopkins University, this track addresses the systemic shift toward New Approach Methodologies (NAMs).
This session is particularly timely given the recent legislative and regulatory momentum toward alternatives. In March 2026, the FDA released draft guidance outlining four core principles for validating NAM evidence in drug development, a move that provides much-needed clarity for manufacturers. Simultaneously, the National Institutes of Health (NIH) has intensified its commitment to this sector through the Complement-ARIE (Complementing Animal Research in Testing) program, which has pledged $150 million over five years to standardize human-based research technologies.
The symposium will offer a deep dive into the practical implementation of organ-on-a-chip technology, neural organoids, and AI-assisted chemical modeling. A highlight of the day will be the discussion on organoid intelligence—a field propelled by recent findings from Hartung and his colleague, Lena Smirnova. Their 2025 research, which demonstrated that lab-grown brain organoids exhibit synaptic plasticity and fundamental learning capabilities, serves as the scientific foundation for the argument that human-derived systems can eventually outperform traditional animal models in predicting human neurological responses to drug compounds.
Chronology of a Regulatory Shift
The decision to feature these topics at PharmSci 360 follows a multi-year trend of federal and industry investment in alternatives to animal testing. The chronology of this transition reveals the urgency with which the pharmaceutical industry is approaching this issue:
- 2022–2023: Increased advocacy from the scientific community regarding the high attrition rates of drugs in clinical trials, often attributed to the failure of animal models to predict human toxicity.
- January 2023: The U.S. Congress passes the FDA Modernization Act 2.0, which allows for the use of non-animal testing methods in drug development, formally ending the requirement for animal data in certain regulatory filings.
- 2025: Landmark studies, including those by Hartung and Smirnova at Johns Hopkins, provide proof-of-concept for high-complexity organoid systems, demonstrating that human-based models can replicate sophisticated biological processes like memory formation.
- March 2026: The FDA releases its comprehensive draft guidance on the submission of NAM-based evidence, providing a regulatory framework for developers to replace or supplement animal data with digital or human-derived biological models.
- October 2026: PharmSci 360 hosts dedicated tracks to operationalize these shifts, focusing on both the "integrity" of the digital data produced by AI and the "validity" of the biological data produced by organoid systems.
Supporting Data and Industry Implications
The economic and scientific implications of this transition are substantial. Current estimates suggest that over 90% of drugs that enter clinical trials fail to receive approval, with a significant portion of these failures due to unforeseen safety or efficacy issues that were not captured by animal models. By moving toward human-derived laboratory systems, the industry aims to reduce the "translational gap" between preclinical research and clinical success.
Data from the NIH’s Complement-ARIE initiative highlights that the investment in these technologies is not merely ethical but efficiency-driven. By automating data collection through organ-on-a-chip systems, researchers can generate more robust datasets in a fraction of the time required for animal-based studies. Furthermore, the integration of AI allows for "chemical read-across," where computers predict the toxicity of new compounds by comparing them against vast, existing databases of chemical properties, significantly lowering the cost of the initial discovery phase.
The Role of Official Oversight and Institutional Trust
The inclusion of these sessions at PharmSci 360 also underscores the role of the NIH and the FDA in fostering an environment where innovation is matched by oversight. Nicole Kleinstreuer, Deputy Director at the National Toxicology Program (NTP), will deliver the afternoon keynote for the NAMs track, focusing on "Building Trust in Non-Animal Safety Science."
Her address is expected to confront the primary hurdle for widespread adoption: the conservative nature of regulatory approval processes. While the technology for organoids and microphysiological systems is rapidly maturing, the pharmaceutical industry remains cautious about relying on these models for safety filings due to the risk of regulatory rejection. By bringing together regulators, startup innovators, and academic researchers, AAPS aims to shorten the feedback loop between the creation of new testing methods and their acceptance by the FDA.
Broader Impact on Global Drug Discovery
The integration of these two tracks—research integrity and post-animal drug development—suggests a holistic approach to the future of the pharmaceutical industry. If research is to be trusted, it must be reproducible and ethically sound. If drug development is to be efficient, it must move away from the limitations of animal biology.
The 2026 PharmSci 360 conference is positioned to act as a catalyst for this transformation. By providing a forum where the challenges of AI-era research integrity are addressed alongside the technical hurdles of NAMs, the AAPS is signaling that the next decade of drug discovery will be defined by a marriage of high-integrity data practices and high-fidelity biological modeling.
For the attendees of the conference, the takeaway is clear: the path to the next generation of therapeutics involves not just better science, but a more rigorous and reliable framework for how that science is conducted, validated, and eventually brought to the bedside. As the industry gathers in New Orleans this October, the focus will be on transitioning these experimental methodologies from the laboratory bench to the core of the global pharmaceutical pipeline.
